Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9550988 Antisense compounds

Patent 9550988 was granted and assigned to Ionis Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 2 Oct, 2024

"update inverses"

edited on 2 Oct, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 12102687 Muscle targeting complexes and uses thereof for treating myotonic dystrophy

0

Edits on 14 Aug, 2024

"update inverses"

edited on 14 Aug, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 12060558 Methods and compositions for treatment of cholesteryl ester storage disease

0

Edits on 27 Jun, 2024

"update inverses"

edited on 27 Jun, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 12018087 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

0

Edits on 19 Jun, 2024

"update inverses"

edited on 19 Jun, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 12012460 Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

0

Edits on 21 Mar, 2024

"update inverses"

edited on 21 Mar, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11931421 Muscle targeting complexes and formulations for treating myotonic dystrophy

0

Edits on 2 Mar, 2024

"update inverses"

edited on 2 Mar, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11911484 Muscle targeting complexes and uses thereof for treating myotonic dystrophy

0

Edits on 9 Feb, 2024

"update inverses"

edited on 9 Feb, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11891605 Reducing intron retention

0

Edits on 30 Jan, 2024

"update inverses"

edited on 30 Jan, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11879125 GalNAc compositions for improving siRNA bioavailability

0

Edits on 19 Jan, 2024

"update inverses"

edited on 19 Jan, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11873490 Antisense oligomers for treatment of conditions and diseases

0

Edits on 27 Dec, 2023

"update inverses"

edited on 27 Dec, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression

0

Edits on 6 Dec, 2023

"Add patent abstract"

edited on 6 Dec, 2023

Edits made to:

Article (+356 characters)

Article

Patent abstract

Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.

Edits on 24 Nov, 2023

"Edit from table cell"

Megan Gustafson

edited on 24 Nov, 2023

Edits made to:

Infobox (+1/-1 properties)

Infobox

Current Assignee

0

Current Assignee

Ionis Pharmaceuticals

Edits on 19 Oct, 2023

"update inverses"

edited on 19 Oct, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11787869 Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness

Edits on 18 Oct, 2023

"update inverses"

edited on 18 Oct, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

US Patent 11786546 Compounds and methods for modulating GFAP

Edits on 30 Sep, 2023

"Add patent inventor(s)"

edited on 30 Sep, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Inventor Names

Eric E. Swayze0

Edits on 16 Jul, 2023

"Remove leading 0 from patent number"

edited on 16 Jul, 2023

Edits made to:

Infobox (+1/-1 properties)

‌

US Patent 09550988 Antisense compounds US Patent 9550988 Antisense compounds

Infobox

Patent Number

095509880

Patent Number

95509880

Edits on 25 May, 2023

"Remove website redirecting to Patent Public Search front page"

edited on 25 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=095509880

Edits on 25 Mar, 2023

"Entity importer update"

edited on 25 Mar, 2023

Infobox

Is a

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

095509880

Date of Patent

January 24, 2017

0

Patent Application Number

124458510

Date Filed

October 18, 2007

0

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=095509880

Patent Primary Examiner

Jennifer McDonald

0

Edits on 15 Jun, 2022

"Entity importer update"

edited on 15 Jun, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Website URL

https://pdfpiw.uspto.gov/.piw?Docid=09550988

Edits on 10 Jan, 2022

"Created via: Entity Importer"

created this topic on 10 Jan, 2022

Edits made to:

Infobox (+8 properties)

‌

US Patent 09550988 Antisense compounds

Infobox

Is a

Current assignee

Patent jurisdiction

United States Patent and Trademark Office

Patent number

09550988

Date of patent

January 24, 2017

Patent application number

12445851

Date Filed

October 18, 2007

Patent primary examiner

Jennifer McDonald

Find more entities like US Patent 9550988 Antisense compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.